Literature DB >> 34859516

An comparison of acute toxicities and patient-reported outcomes between intensity-modulated proton therapy and volumetric-modulated arc therapy after ipsilateral radiation for head and neck cancers.

Elizabeth B Jeans1, Satomi Shiraishi1, Gohar Manzar1, Lindsay K Morris1, Adam Amundson1, Lisa A McGee2, Jean-Claude Rwigema2, Michelle Neben-Wittich1, David M Routman1, Daniel J Ma1, Samir H Patel2, Robert L Foote1, Scott C Lester1.   

Abstract

BACKGROUND: Intensity-modulated proton therapy (IMPT) demonstrates superior dose distribution over volumetric-modulated arc therapy (VMAT) for sparing organs-at-risk (OARs) in ipsilateral radiotherapy. To determine a clinical benefit, assessment of patient-reported outcomes (PRO) and physician-reported toxicities alongside a dosimetric analysis is needed.
METHODS: Plans were analyzed for dosimetric differences. PROs were compared for patients undergoing ipsilateral curative-intent radiotherapy for tonsil and salivary gland cancers with VMAT or IMPT from 2015 to 2020. Physician-reported toxicities were compared.
RESULTS: In 40 patients, IMPT was associated with decreased dose to multiple OARs and less deterioration in the following PROs: pain, swallowing function, dry mouth, sticky saliva, sensory change, cough, speech, feeling ill, and social eating. Physician-reported toxicities demonstrated less oral pain.
CONCLUSION: IMPT is associated with decreased dose to OARs and less patient-reported acute deterioration in multiple head and neck domains. A strong consideration for IMPT in ipsilateral head and neck patients with cancer is warranted.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  IMPT; head and neck cancer; ipsilateral neck radiotherapy; proton radiotherapy; tonsil and salivary cancer

Mesh:

Year:  2021        PMID: 34859516     DOI: 10.1002/hed.26937

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

Review 1.  Proton Therapy for Squamous Cell Carcinoma of the Head and Neck: Early Clinical Experience and Current Challenges.

Authors:  Sandra Nuyts; Heleen Bollen; Sweet Ping Ng; June Corry; Avraham Eisbruch; William M Mendenhall; Robert Smee; Primoz Strojan; Wai Tong Ng; Alfio Ferlito
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

2.  CD9- and CD81-positive extracellular vesicles provide a marker to monitor glioblastoma cell response to photon-based and proton-based radiotherapy.

Authors:  Sara Jennrich; Martin Pelzer; Tobias Tertel; Benjamin Koska; Melanie Vüllings; Basant Kumar Thakur; Verena Jendrossek; Beate Timmermann; Bernd Giebel; Justine Rudner
Journal:  Front Oncol       Date:  2022-09-20       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.